4,209
Participants
Start Date
January 6, 2005
Primary Completion Date
November 1, 2006
Study Completion Date
December 4, 2006
SB213503 lot 1
SB213503 lot 1 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
SB213503 lot 2
SB213503 lot 2 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
SB213503 lot 3
SB213503 lot 3 vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
Infanrix
Infanrix vaccine was administered as a single dose by intramuscular injection in the deltoid at Day 0.
IPOL
IPOL vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
M-M-R II
M-M-R II vaccine was administered as a single dose by subcutaneous injection in the deltoid at Day 0.
GSK Investigational Site, Mechanicsville
GSK Investigational Site, Columbus
GSK Investigational Site, Little Rock
GSK Investigational Site, Fresno
GSK Investigational Site, Daly City
GSK Investigational Site, Redwood City
GSK Investigational Site, San Francisco
GSK Investigational Site, Antioch
GSK Investigational Site, Fairfield
GSK Investigational Site, Fremont
GSK Investigational Site, Hayward
GSK Investigational Site, San Ramon
GSK Investigational Site, Pleasanton
GSK Investigational Site, Vallejo
GSK Investigational Site, Walnut Creek
GSK Investigational Site, Oakland
GSK Investigational Site, Richmond
GSK Investigational Site, Santa Clara
GSK Investigational Site, San Jose
GSK Investigational Site, Santa Rosa
GSK Investigational Site, Roseville
GSK Investigational Site, Vacaville
GSK Investigational Site, Sacramento
GSK Investigational Site, Sacramento
Lead Sponsor
GlaxoSmithKline
INDUSTRY